An observational study in Non-Segmental Vitiligo, sponsored by AbbVie. Completed at 4 sites in China. Open to participants aged 12 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by AbbVie · Observational
The purpose of this study is to evaluate the patterns of treatment, healthcare resources utilized and the burdens associated with non-segmental vitiligo (NSV) amongst participants in China
This study is a cross-sectional, multicenter, observational study of vitiligo patients in China. The cross-sectional design is sufficient to characterize the overall current burden of NSV.
Cross-Sectional
AbbVie is the lead sponsor of 953 studies on the registry; 136 are open to participants now.
Of its 350 completed or terminated interventional studies of FDA-regulated products, 210 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Chinese patients with non-segmental vitiligo and 5≤T-VASI\<50 will be included. The NSV patients will be consecutively enrolled via convenience sampling in this study.
Exclusion Criteria:
Total Vitiligo Area Scoring Index (T-VASI)
The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100, with higher scores indicating more severe disease.
Time frame: At Inclusion Visit (Day 1)
Vitiligo Quality of Life Scale (VitiQoL)
The VitiQoL is an 16-item instrument assessing impact of vitiligo on quality of life. 15 items are scored on a 7-point Likert scale, ranging from "not at all" to "all the time". An additional item (not contributing to total score) assesses current severity of condition on a 7-point scale ranging from "no skin involvement" to "most severe case"
Time frame: At Inclusion Visit (Day 1)
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie